Use of metabolic pathway flux information in targeted cancer drug design

Drug Discovery Today: Therapeutic Strategies

Volumn 1, Issue 4, 2004, Pages 435-443

  Boros, László G ^a   Serkova, Natalie J ^b   Cascante, Marta S ^c   Lee, Wai Nang Paul ^a  

^a UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CGP 69846A; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HEXOKINASE; IMATINIB; IMMUNOLIPOSOME; MONOCLONAL ANTIBODY; STABLE ISOTOPE;

ACCURACY; APOPTOSIS; ARTICLE; CANCER GENETICS; CELL LABELING; CELL METABOLISM; DRUG DESIGN; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; ENCAPSULATION; ENZYME ANALYSIS; ENZYME REGULATION; GENE TARGETING; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METABOLOMICS; PHENOTYPE; PREDICTION; PROTEIN TARGETING; PROTEOMICS; TUMOR CELL;

EID: 13344285960     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2004.11.016     Document Type: Review

References (37)

1. L.G. Boros et al. A metabolic hypothesis of cell growth and death in pancreatic cancer Pancreas 24 2002 26-33
2. H.C. Pitot J.P. Jost Control of biochemical expression in morphologically related cells in vivo and in vitro Natl. Cancer Inst. Monogr. 26 1967 145-166
3. P.A. te Boekhorst et al. Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukaemia Leukemia 9 1995 1025-1031
4. T.A. Smith FDG uptake, tumor characteristics and response to therapy: A review Nucl. Med. Commun. 19 1998 97-105
5. A.G. Schwartz et al. Inhibition of tumor development by dehydroepiandrosterone and related steroids Toxicol. Pathol. 14 1986 357-362
6. E. Eigenbrodt et al. Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells Crit. Rev. Oncog. 3 1992 91-115
7. F.P. Kuhajda Fatty-acid synthase and human cancer: New perspectives on its role in tumor biology Nutrition 16 2000 202-208
8. A. Baron et al. Fatty acid synthase: A metabolic oncogene in prostate cancer? J. Cell. Biochem. 91 2004 47-53
9. S.W. Cowan-Jacob et al. Imatinib (STI571) resistance in chronic myelogenous leukemia: Molecular basis of the underlying mechanisms and potential strategies for treatment Mini Rev. Med. Chem. 4 2004 285-299
10. N.P. Shah et al. Overriding imatinib resistance with a novel ABL kinase inhibitor Science 305 2004 399-401
11. V. Guillemard H.U. Saragovi Novel approaches for targeted cancer therapy Curr. Cancer Drug Targets 4 2004 313-326
12. W. Hu J.J. Kavanagh Anticancer therapy targeting the apoptotic pathway Lancet Oncol. 4 2003 721-729
13. P. Danzon A. Towse The economics of gene therapy and of pharmacogenetics Value Health 5 2002 5-13
14. C. Schmidt Metabolomics takes its place as latest up-and-coming "omic" science J. Natl. Cancer Inst. 96 2004 732-734
15. J.L. Griffin Metabolic profiles to define the genome: Can we hear the phenotypes? Philos. Trans. R. Soc. Lond. B Biol. Sci. 359 2004 857-871
16. L.G. Boros et al. Metabolic profiling of cell growth and death in cancer: Applications in drug discovery Drug Discov. Today 7 2002 364-372
17. L.G. Boros et al. Metabolic biomarker and kinase drug target discovery in cancer using stable isotope-based dynamic metabolic profiling (SIDMAP) Curr. Cancer Drug Targets 3 2003 445-453
18. L.G. Boros et al. Defective RNA ribose synthesis in fibroblasts from patients with thiamine-responsive megaloblastic anemia (TRMA) Blood 102 2003 3556-3561
19. R. Green Mystery of thiamine-responsive megaloblastic anemia unlocked Blood 102 2003 3464-3465
20. L.G. Boros et al. Oxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and tumor cell proliferation Cancer Res. 57 1997 4242-4248
21. L.G. Boros et al. Genistein inhibits non-oxidative ribose synthesis in MIA pancreatic adenocarcinoma cells: A new mechanism of controlling tumor growth Pancreas 22 2001 1-7
22. L.G. Boros et al. Wheat germ extract decreases glucose uptake and RNA ribose formation but increases fatty acid synthesis in MIA pancreatic adenocarcinoma cells Pancreas 23 2001 141-147
23. Boros, L.G. (2004) Metabolic profile of inflammatory breast cancer: aiding diagnosis and treatment. George Washington University and the IBC Research Foundation co-sponsored "IBC Mini Symposium" hosted by George Washington University: http://www.ibcresearch.org/ibcminisymposium/
24. J. Bentley et al. Glucose transport regulation by p210 Bcr-Abl in a chronic myeloid leukaemia model Br. J. Haematol. 112 2001 212-215
25. H. Osawa et al. Analysis of the signaling pathway involved in the regulation of hexokinase II gene transcription by insulin J. Biol. Chem. 271 1996 16690-16694
26. J. Boren et al. Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells J. Biol. Chem. 276 2001 37747-37753
27. S. Gottschalk et al. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells Clin. Cancer Res. 10 2004 6661-6668
28. L. Sabate et al. A model of the pentose phosphate pathway in rat liver cells Mol. Cell. Biochem. 142 1995 9-17
29. B. Comin-Anduix et al. The effect of thiamine supplementation on tumor proliferation: A metabolic control analysis study Eur. J. Biochem. 268 2001 4177-4182
30. N.J. Donato et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571 Blood 101 2003 690-698
31. F.X. Mahon et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance Blood 96 2000 1070-1079
32. J.E. Dancey B. Freidlin Targeting epidermal growth factor receptor - are we missing the mark? Lancet 362 2003 62-64
33. E.R. Nemecek D.C. Matthews Use of radiolabeled antibodies in the treatment of childhood acute leukemia Pediatr. Transplant. 3 2003 89-94
34. E.L. Sievers Targeted therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugates Cancer Chemother. Pharmacol. 46 2000 S18-S22
35. C.M. Rudin et al. Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer Clin. Cancer Res. 7 2001 1214-1220
36. S. Matzku et al. Tumor targeting with antibody-coupled liposomes: failure to achieve accumulation in xenografts and spontaneous liver metastases Cancer Immunol. Immunother. 31 1990 285-291
37. W.K. Hofmann et al. Mechanisms of resistance to STI571 (Imatinib) in Philadelphia-chromosome positive acute lymphoblastic leukemia Leuk. Lymphoma 45 2004 655-660